Poznan University of Medical Sciences

Vaginal Prasterone Versus Estriol in Women With Pelvic Floor Disorders

No phaseCompleted202274 people2 Oct 2026clinicaltrials.gov

NCT07180953

Phase 4Completed202590 people18 Sept 2025clinicaltrials.gov

NCT07180940

Phase 4Recruiting2025150 people18 Sept 2025clinicaltrials.gov

NCT07061678

Phase 4Completed202590 people11 Jul 2025clinicaltrials.gov

NCT07023120

Phase 4Completed2025120 people15 Jun 2025clinicaltrials.gov

NCT06789042

Phase 4Completed202560 people23 Jan 2025clinicaltrials.gov

NCT06789029

Phase 4Recruiting202560 people23 Jan 2025clinicaltrials.gov

NCT06616220

Phase 4Completed202460 people27 Sept 2024clinicaltrials.gov

NCT06470334

Phase 4Completed202460 people24 Jun 2024clinicaltrials.gov

NCT06470204

Phase 4Completed202460 people24 Jun 2024clinicaltrials.gov

NCT06470139

Phase 4Completed202460 people24 Jun 2024clinicaltrials.gov

NCT06470100

Phase 4Completed202490 people24 Jun 2024clinicaltrials.gov

NCT06304324

Phase 4Status unknown202490 people12 Mar 2024clinicaltrials.gov

NCT06233617

Phase 4Completed202490 people31 Jan 2024clinicaltrials.gov

NCT06233604

Phase 4Status unknown202430 people31 Jan 2024clinicaltrials.gov

NCT06233565

Phase 4Completed202490 people31 Jan 2024clinicaltrials.gov

NCT06086431

Phase 4Completed202390 people17 Oct 2023clinicaltrials.gov

NCT06086418

Phase 4Completed202390 people17 Oct 2023clinicaltrials.gov

NCT06086392

Phase 4Completed202390 people17 Oct 2023clinicaltrials.gov

NCT05887778

Phase 4Completed202390 people5 Jun 2023clinicaltrials.gov